Wed, Jan 28, 2015, 5:40 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mtdsus mtdsus Sep 15, 2012 11:17 AM Flag

    JELIS study proved Epadel effective in preventing major Coronary events.Reduce-IT-Outcome study changed to more specific events

    Amarin 101 changed in March,2012 the Outcome study--Reduce-IT.
    From : Incidence of Cardiovascularazation
    To: Composite endpoint of CV death,MI,Stroke,Coronary revacularization and hospitalization for unstable angina.
    Various studies--Recent one in JAMA on Fish Oil (mostly Over the counter Fish Oil) andORIGIN study -6 years-in NE journal of medicine--showed no significant benefit.
    JELIS study: For Epadel--90% pure EPA sold in Japan--showed
    1) 19% relative reduction in major Coronary events
    2) Unstable angina and non fatal coronary events were also significantly reduced.
    JELIS study enrolled 18645 patients from 1996-95 and was completed in 2005.It was the largest scientific study in Japan.
    VASCEPA or AMR101 are highly purified EPA--Vascepa is 96% pure vs.Epadel 90% pure EPA.
    Marine Trial data showed significant lowering of LDL and C-RP
    What is C-RP? It is is GOLDEN MARKER for Inflammation and Coronary artery disease according to Dr.Eric Topol,Chief of Cleveland Clinic Cardiology dept.-rated #1 in USA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Should be called the Ka-Ching study. It'll end early based on stellar results

      Sentiment: Strong Buy

    • MTDSUS
      What you want to look for is the sub group in the Jelis Trial ----combination of high TG's and low HDL --- there I think there was a 53 % reduction in events
      I was interviewed by the Reduce trial group re participating in the trial ---they want patients with diabetes of 50 % stenois in 2 coronary arteries ( now with stents ) ---they are intent on this trial deciding once and for all , if high doses's of purified EPA reduce Tg's will this reduce heart attacks and other such "events "

      The "event " lines in Jelis started to diverge after 2 yrs ---so dosing for Reduce it ,began late 2011 , so by late 2013 they should see trends developing.

      An important note on the Jelis trial ---comprised of 69% Japanese women --who were eating fish at least 5 times a week
      Akanz

      Sentiment: Buy

    • Mtd, thanks for posting. I agree wholeheartedly. As others have noted on this board, the Jelis study was a relatively healthy population with fish a staple in diet and still showed favorable results. The Reduce-It study is in a high risk population already with heart disease or at high risk for heart disease. It likely will improve upon the Jelis findings. The inclusion criteria for the study using Vascepa:

      Inclusion Criteria:
      Men and non-pregnant or sterile women ages 45 and older
      Hypertriglyceridemia
      On statin therapy for at least four weeks
      Either having established Cardiovascular Disease or at high risk for Cardiovascular Disease

      Sentiment: Strong Buy

    • I believe strongly that VASCEPA will prove to be far more effective in reducing coronary events than Epadel. But more importantly:
      1) Fish oil sold in over the counter are USELESS-ineffective.
      2) Lovaza is unproven to reduce Coronary events.
      3) Marine trial data is the only evidence so far for VASCEPA or AMR101.
      In 2015 or 2016--OUTCOME STUDY will provide Scientific PROOF for VASCEPA.
      Dr.Bhatt is very hopeful .

 
AMRN
1.030.000(0.00%)Jan 28 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.